<p>添加</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>作為您在 Google 上的首選新聞來源</p>
<p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>立即添加</p>
<p>Sanuwave Health, Inc.(SNWV) 是一家醫療設備公司，週五表示預計其第四季度收入將在 1330 萬美元至 1340 萬美元之間，比去年同期增長 29% 至 30%。</p>
<p>Sanuwave Health 的首席執行官 Morgan Frank 表示：“正如我們在發佈第三季度財報時討論的那樣，2025 年下半年是傷口護理領域劇烈轉型的時期，皮膚替代品和同種異體移植物的報銷率降低深刻重塑了我們的市場。這種重組時期總是充滿機會。”</p>
<p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
<p>商業新聞</p>

SNWV

<p>SANUWAVE Health, Inc. (SNWV) 宣佈預計其第四季度收入將在 1330 萬美元到 1340 萬美元之間，較去年增長 29% 至 30%。首席執行官 Morgan Frank 強調，由於報銷率的變化，傷口護理市場正在進行轉型，他將其視為增長的機會</p>

<p>Add</p>
<div class="lb-trans"><p>添加</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png" alt="" original-src="https://cdn.rttnews.com/images/v4/RTTNews-Logo-224x61.png"/></p>
<p>as your preferred news source on Google</p>
<div class="lb-trans"><p>作為您在 Google 上的首選新聞來源</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cdn.rttnews.com/images/v4/google.png" alt="" original-src="https://cdn.rttnews.com/images/v4/google.png"/></p>
<p>Add Now</p>
<div class="lb-trans"><p>立即添加</p>
</div><p>Sanuwave Health, Inc.(SNWV), a medical devices company, said on Friday that it expects its fourth-quarter revenue to be in the range of $13.3 million to $13.4 million, an increase of 29% to 30% from the same period last year.</p>
<div class="lb-trans"><p>Sanuwave Health, Inc.(SNWV) 是一家醫療設備公司，週五表示預計其第四季度收入將在 1330 萬美元至 1340 萬美元之間，比去年同期增長 29% 至 30%。</p>
</div><p>Morgan Frank, CEO of Sanuwave Health, said: &#34;As we discussed when releasing Q3, the second half of 2025 was a time of intense transition in the wound care space as reductions to reimbursement rates for skin-substitutes and allografts profoundly reshaped our market. Periods of such rearrangement are always times of opportunity.&#34;</p>
<div class="lb-trans"><p>Sanuwave Health 的首席執行官 Morgan Frank 表示：“正如我們在發佈第三季度財報時討論的那樣，2025 年下半年是傷口護理領域劇烈轉型的時期，皮膚替代品和同種異體移植物的報銷率降低深刻重塑了我們的市場。這種重組時期總是充滿機會。”</p>
</div><p>For comments and feedback contact: editorial@rttnews.com</p>
<div class="lb-trans"><p>如有意見和反饋，請聯繫：editorial@rttnews.com</p>
</div><p>Business News</p>
<div class="lb-trans"><p>商業新聞</p>
</div>

SANUWAVE Health 第四季度初步收入上升